| 15.18 -0.38 (-2.44%) | 07-31 10:56 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.74 |
1-year : | 24.38 |
| Resists | First : | 18.61 |
Second : | 20.87 |
| Pivot price | 16.45 |
|||
| Supports | First : | 14.96 |
Second : | 12.44 |
| MAs | MA(5) : | 15.5 |
MA(20) : | 17.27 |
| MA(100) : | 18.51 |
MA(250) : | 19.37 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 7.1 |
D(3) : | 7.6 |
| RSI | RSI(14): 33.4 |
|||
| 52-week | High : | 25.31 | Low : | 14.68 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SRPT ] has closed above bottom band by 18.6%. Bollinger Bands are 10.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.67 - 15.73 | 15.73 - 15.79 |
| Low: | 14.89 - 14.96 | 14.96 - 15.02 |
| Close: | 15.45 - 15.56 | 15.56 - 15.66 |
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Fri, 31 Jul 2026
SRPT|Sarepta Therapeutics Inc|Price:15.560|Chg%:+0.025 - TradingKey
Thu, 30 Jul 2026
BlackRock (NYSE: BLK) discloses 16.6M-share Sarepta Therapeutics (SRPT) position in 13G/A - Stock Titan
Wed, 29 Jul 2026
Form 4 Sarepta Therapeutics Inc For: 29 July By Investing.com - Investing.com Canada
Wed, 29 Jul 2026
Earnings Preview: Sarepta Therapeutics (SRPT) Q2 Earnings Expected to Decline - Yahoo Finance
Tue, 28 Jul 2026
Sarepta Therapeutics Appoints Michael Severino as CEO - The Globe and Mail
Mon, 27 Jul 2026
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 106 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 4.2 (%) |
| Held by Institutions | 99.5 (%) |
| Shares Short | 28,490 (K) |
| Shares Short P.Month | 25,170 (K) |
| EPS | 0.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.26 |
| Profit Margin | 2.9 % |
| Operating Margin | 49 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 4.9 % |
| Qtrly Rev. Growth | -1.9 % |
| Gross Profit (p.s.) | 4.45 |
| Sales Per Share | 20.64 |
| EBITDA (p.s.) | 0.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 175 (M) |
| Levered Free Cash Flow | 205 (M) |
| PE Ratio | 43.22 |
| PEG Ratio | -0.1 |
| Price to Book value | 1.06 |
| Price to Sales | 0.73 |
| Price to Cash Flow | 9.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|